Menu
Search
|

Menu

Close
X

Lipocine Inc LPCN.OQ (NASDAQ Stock Exchange Capital Market)

1.18 USD
-- (--)
As of Feb 22
chart
Previous Close 1.18
Open --
Volume --
3m Avg Volume 62,607
Today’s High --
Today’s Low --
52 Week High 5.32
52 Week Low 1.16
Shares Outstanding (mil) 21.20
Market Capitalization (mil) 25.01
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.799
FY16
-1.039
FY15
-1.091
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.59
Price to Sales (TTM)
vs sector
--
8.08
Price to Book (MRQ)
vs sector
1.05
5.24
Price to Cash Flow (TTM)
vs sector
--
25.98
Total Debt to Equity (MRQ)
vs sector
0.00
15.60
LT Debt to Equity (MRQ)
vs sector
0.00
12.18
Return on Investment (TTM)
vs sector
-71.95
13.67
Return on Equity (TTM)
vs sector
-71.95
15.40

EXECUTIVE LEADERSHIP

Mahesh Patel
Chairman of the Board, President, Chief Executive Officer, Since 2014
Salary: $370,800.00
Bonus: --
Morgan Brown
Chief Financial Officer, Executive Vice President, Since 2013
Salary: $263,333.00
Bonus: $25,000.00
Gregory Bass
Executive Vice President, Chief Commercial Officer, Since 2017
Salary: --
Bonus: --
Stephen Hill
Lead Independent Director, Since 2014
Salary: --
Bonus: --
Jeffrey Fink
Director, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

675 S Arapeen Dr Ste 202
SALT LAKE CITY   UT   84108-1295

Phone: +1801.9947383

Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.

SPONSORED STORIES